- Home
- ETON
as 11-15-2024 4:00pm EST
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | DEER PARK |
| Market Cap: | 199.5M | IPO Year: | 2018 |
| Target Price: | $12.00 | AVG Volume (30 days): | 212.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $11.11 | Next Earning Date: | 11-12-2024 |
| Revenue: | $34,677,000 | Revenue Growth: | 5.64% |
| Revenue Growth (this year): | 19.61% | Revenue Growth (next year): | 82.71% |
Stock Insider Trading Activity of Eton Pharmaceuticals Inc. (ETON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | ETON | 10% Owner | Oct 23 '24 | Buy | $7.98 | 10,000 | $79,814.00 | 2,770,000 | |
| Opaleye Management Inc. | ETON | 10% Owner | Oct 4 '24 | Buy | $7.01 | 62,070 | $434,136.74 | 2,770,000 | |
| Opaleye Management Inc. | ETON | 10% Owner | Sep 10 '24 | Buy | $4.70 | 107,500 | $504,875.00 | 2,770,000 |
Latest Eton Pharmaceuticals Inc. News
ETON Breaking Stock News: Dive into ETON Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Eton Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
4 days ago
Q3 2024 Eton Pharmaceuticals Inc Earnings Call
GuruFocus.com
5 days ago
Eton Pharmaceuticals Inc (ETON) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...
GlobeNewswire
5 days ago
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
GuruFocus.com
6 days ago
What To Expect From Eton Pharmaceuticals Inc (ETON) Q3 2024 Earnings
GlobeNewswire
10 days ago
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
GlobeNewswire
11 days ago
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
TipRanks
19 days ago
Eton Pharmaceuticals price target raised to $15 from $10 at Craig-Hallum
Compare ETON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETON Eton Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.